The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

被引：5

作者：

El-Ashwah, Shaimaa ^{[1
]}

Salmanton-Garcia, Jon ^{[2
,3
,4
]}

Bilgin, Yavuz M. ^{[5
]}

Itri, Federico ^{[6
]}

Zak, Pavel ^{[7
]}

Weinbergerova, Barbora ^{[8
]}

Verga, Luisa ^{[9
,10
]}

Omrani, Ali S. ^{[11
]}

Silva, Maria Gomes da ^{[12
]}

Szotkowski, Tomas ^{[13
]}

Marchetti, Monia ^{[14
]}

Buquicchio, Caterina ^{[15
]}

Nucci, Marcio ^{[16
]}

Schoenlein, Martin ^{[17
]}

Farina, Francesca ^{[18
]}

Besson, Caroline ^{[19
,20
]}

Prezioso, Lucia ^{[21
]}

Nizamuddin, Summiya ^{[22
]}

Davila-Valls, Julio ^{[23
]}

Martin-Perez, Sonia ^{[23
]}

Bonuomo, Valentina ^{[24
,25
]}

Van Doesum, Jaap ^{[26
]}

Tisi, Maria Chiara ^{[27
]}

Passamonti, Francesco ^{[28
,29
]}

Mendez, Gustavo-Adolfo ^{[30
]}

Meers, Stef ^{[31
]}

Maertens, Johan ^{[32
,33
]}

Lopez-Garcia, Alberto ^{[34
]}

Glenthoj, Andreas ^{[35
]}

Bonnani, Matteo ^{[36
]}

Rinaldi, Ikhwan ^{[37
]}

Ormazabal-Velez, Irati ^{[38
]}

Labrador, Jorge ^{[39
]}

Kulasekararaj, Austin ^{[40
]}

Espigado, Ildefonso ^{[41
]}

Demirkan, Fatih ^{[42
]}

De Jonge, Nick ^{[43
]}

Collins, Graham P. ^{[44
]}

Calbacho, Maria ^{[45
]}

Blennow, Ola ^{[46
]}

Al-Khabori, Murtadha ^{[47
]}

Adzic-Vukicevic, Tatjana ^{[48
]}

Arellano, Elena ^{[41
]}

Miskovic, Bojana ^{[48
,49
]}

Mladenovic, Milos ^{[48
,49
]}

Nordlander, Anna ^{[46
]}

Racil, Zdenek ^{[50
]}

Ammatuna, Emanuele ^{[26
]}

Cordoba, Raul ^{[51
]}

Hersby, Ditte Stampe ^{[52
]}

机构：

[1] Mansoura Univ, Oncol Ctr, Mansoura, Egypt

[2] Univ Cologne, Univ Hosp Cologne, Inst Translat Res, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany

[3] Univ Cologne, Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Dept Internal Med 1, Cologne, Germany

[4] Univ Cologne, Univ Hosp Cologne, Excellence Ctr Med Mycol ECMM, Cologne, Germany

[5] ADRZ, Dept Internal Med, Goes, Netherlands

[6] San Luigi Gonzaga Hosp Orbassano, Orbassano, Italy

[7] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic

[8] Masaryk Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[9] Azienda Osped San Gerardo Monza, Monza, Italy

[10] Univ Milano Bicocca, Milan, Italy

[11] Hamad Med Corp, Communicable Dis Ctr, Doha, Qatar

[12] Portuguese Inst Oncol, Lisbon, Portugal

[13] Univ Hosp Olomouc, Olomouc, Czech Republic

[14] Azienda Osped Nazl SS Antonio & Biagio Cesare Arr, Alessandria, Italy

[15] Osped Dimiccoli Barletta, Ematol Con Trapianto, Barletta, Italy

[16] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil

[17] Univ Med Ctr Hamburg Eppendorf, Sect Pneumol, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[18] IRCCS Osped San Raffaele, Milan, Italy

[19] Ctr Hosp Versailles, Le Chesnay, France

[20] Univ Paris Saclay, UVSQ, INSERM, Equipe Exposome & Heredite,CESP, Villejuif, France

[21] Hosp Univ Parma, Hematol & Bone Marrow Unit, Parma, Italy

[22] Mem Canc Hosp & Res Ctr, Lahore, Pakistan

[23] Hosp Nuestra Senora Sonsoles, Avila, Spain

[24] Univ Verona, Sect Hematol, Dept Med, Verona, Italy

[25] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

[26] Univ Med Ctr Groningen, Groningen, Netherlands

[27] Osped San Bortolo, Vicenza, Italy

[28] Univ Insubria, Dept Med & Surg, Varese, Italy

[29] Osped Circolo Varese, ASST Sette Laghi, Varese, Italy

[30] Hosp Escuela Agudos Dr Ramon Madariaga, Posadas, Argentina

[31] AZ KLINA, Brasschaat, Belgium

[32] KULeuven, Dept Microbiol Immunol & Transplantat, Leuven, Belgium

[33] UZ Leuven, Dept Hematol, Leuven, Belgium

[34] Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst IIS FJD, Madrid, Spain

[35] Copenhagen Univ Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark

[36] Fdn Policlin Univ Agostino Gemelli IRCCS, Hematol Unit, Rome, Italy

[37] Univ Indonesia, Dept Internal Med, Div Hematol & Med Oncol, Cipto Mangunkusumo Hosp, Jakarta, Indonesia

[38] Complejo Hosp Navarra, Iruna Pamplona, Spain

[39] Hosp Univ Burgos, Res Unit, Dept Hematol, Burgos, Spain

[40] Kings Coll Hosp London, London, England

[41] Univ Seville, Univ Hosp Virgen Macarena, Inst Biomed Sevilla IBIS CSIC, Dept Hematol,Univ Hosp Virgen Rocio,Dept Med, Seville, Spain

[42] Dokuz Eylul Univ, Div Hematol, Izmir, Turkiye

[43] Amsterdam UMC, Locat VUmc, Amsterdam, Netherlands

[44] Churchill Hosp, NIHR Oxford Biomed Res Ctr, Oxford, England

[45] Hosp Univ 12 Octubre, Madrid, Spain

[46] Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden

[47] Sultan Qaboos Univ Hosp, Muscat, Oman

[48] COVID 19 Hosp Batajn, Belgrade, Serbia

[49] Univ Clin Ctr Serbia, Clin Orthoped Surg & Traumatol, Belgrade, Serbia

[50] Inst Hematol & Blood Transfus, Prague, Czech Republic

来源：

LEUKEMIA & LYMPHOMA | 2024年 / 65卷 / 02期

关键词：

Chronic myeloid leukemia; tirosine kinase inhibitor; COVID-19; SARS-CoV-2; neoplasia; vaccines; KINASE INHIBITORS;

D O I：

10.1080/10428194.2023.2280886

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.

引用

页码：199 / 208

页数：10